|
1.
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Di Fiore PP, Pierce JH, Fleming TP, et al:
Overexpression of the human EGF receptor confers an EGF-dependent
transformed phenotype to NIH 3T3 cells. Cell. 51:1063–1070.
1987.PubMed/NCBI
|
|
3.
|
Riechmann L, Clark M, Waldmann H and
Winter G: Reshaping human antibodies for therapy. Nature.
332:323–327. 1988. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Baselga J, Pfister D, Cooper MR, et al:
Phase I studies of anti-epidermal growth factor receptor chimeric
antibody C225 alone and in combination with cisplatin. J Clin
Oncol. 18:904–914. 2000.PubMed/NCBI
|
|
5.
|
Robert F, Ezekiel MP, Spencer SA, et al:
Phase I study of anti-epidermal growth factor receptor antibody
cetuximab in combination with radiation therapy in patients with
advanced head and neck cancer. J Clin Oncol. 19:3234–3243.
2001.PubMed/NCBI
|
|
6.
|
Peeters M, Balfour J and Arnold D: Review
article: panitumumab – a fully human anti-EGFR monoclonal antibody
for treatment of metastatic colorectal cancer. Aliment Pharmacol
Ther. 28:269–281. 2008.
|
|
7.
|
Lynch DH and Yang XD: Therapeutic
potential of ABX-EGF: a fully human anti-epidermal growth factor
receptor monoclonal antibody for cancer treatment. Semin Oncol.
29:47–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Schrag D, Chung KY, Flombaum C and Saltz
L: Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer
Inst. 97:1221–1224. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Van Cutsem E, Siena S, Humblet Y, et al:
An open-label, single-arm study assessing safety and efficacy of
panitumumab in patients with metastatic colorectal cancer
refractory to standard chemotherapy. Ann Oncol. 19:92–98.
2008.PubMed/NCBI
|
|
10.
|
Tejpar S, Piessevaux H, Claes K, et al:
Magnesium wasting associated with epidermal-growth-factor
receptor-targeting antibodies in colorectal cancer: a prospective
study. Lancet Oncol. 8:387–394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Fakih M: Management of anti-EGFR-targeting
monoclonal antibody-induced hypomagnesemia. Oncology. 22:74–76.
2008.PubMed/NCBI
|
|
12.
|
Sobrero A, Fehrenbacher L and Rivera F:
Randomized Phase III trial of cetuximab plus irinotecan versus
irinotecan alone for metastatic colorectal cancer in 1298 patients
who have failed prior oxaliplatin-based therapy. In: Program and
abstracts of the American Association for Cancer Research Annual
Meeting; Los Angeles. April 2007;
|
|
13.
|
Van Cutsem E, Nowacki M and Lang I:
Randomized Phase III study of irinotecan and 5-FU/FA with or
without cetuximab in the first-line treatment of patients with
metastatic colorectal cancer (mCRC): the CRYSTAL trial. In: Program
and abstracts of the American Association for Cancer Research
Annual Meeting; Los Angeles. April 2007;
|
|
14.
|
Konrad M, Schlingmann KP and Gudermann T:
Insights into the molecular nature of magnesium homeostasis. Am J
Physiol Renal Physiol. 286:F599–F605. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Hoenderop JG and Bindels RJ: Epithelial
Ca2+ and Mg2+ channels in health and disease.
J Am Soc Nephrol. 16:15–26. 2005.
|
|
16.
|
Voets T, Nilius B, Hoefs S, et al: TRPM6
forms the Mg2+ influx channel involved in intestinal and
renal Mg2+ absorption. J Biol Chem. 279:19–25.
2004.PubMed/NCBI
|
|
17.
|
Gesualdo L, Di Paolo S, Calabro A, et al:
Expression of epidermal growth factor and its receptor in normal
and diseased human kidney: an immunohistochemical and in situ
hybridization study. Kidney Int. 49:656–665. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Sack E and Talor Z: High affinity binding
sites for epidermal growth factor (EGF) in renal membranes. Biochem
Biophys Res Commun. 154:312–317. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Groenestege WM, Thebault S, van der Wijst
J, et al: Impaired basolateral sorting of pro-EGF causes isolated
recessive renal hypomagnesemia. J Clin Invest. 117:2260–2267. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Schlingmann KP, Weber S, Peters M, et al:
Hypomagnesemia with secondary hypocalcemia is caused by mutations
in TRPM6, a new member of the TRPM gene family. Nat Genet.
31:166–170. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Knaus WA, Wagner DP, Draper EA, et al: The
APACHE III prognostic system. Risk prediction of hospital mortality
for critically ill hospitalized adults. Chest. 100:1619–1636. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Lis CG, Grutsch JF, Vashi PG and
Lammersfeld CA: Is serum albumin an independent predictor of
survival in patients with breast cancer? JPEN J Parenter Enteral
Nutr. 27:10–15. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Seaton K: Albumin, cancer and pregnancy. J
Natl Med Assoc. 94:629–630. 2002.PubMed/NCBI
|
|
24.
|
Gobbi PG, Gendarini A, Crema A, et al:
Serum albumin in Hodgkin's disease. Cancer. 55:389–393. 1985.
|
|
25.
|
Emerson TE Jr: Unique features of albumin:
a brief review. Crit Care Med. 17:690–694. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Peters T: All About Albumin. New York
Academic Press; New York: 1996
|
|
27.
|
Seaton K: Albumin concentration controls
cancer. J Natl Med Assoc. 93:490–493. 2001.PubMed/NCBI
|
